published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

published_or_final_version / Medicine / Master / Doctor of Medicine

Antiviral therapy for patients infected with hepatitis B virus is only partially efficient. The field is in high demand for understanding the connections between the virus, immune responses, short-term and long-term drug efficacy and the overall health of the liver. A mathematical model was introduced in 2009 to help elucidate the host-virus dynamics after the start of therapy. The model allows the study of complicated viral patterns observed in HBV patients. In our research, we will analyze this model to determine the biological markers (e.g. liver proliferation, immune responses, and drug efficacy) that determine the different decay patterns. We will also investigate how such markers affect the length of therapy and the amount of liver damage. / Master of Science

Law Man Yee. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (leaves 123-132). / Abstracts in English and Chinese; appendix in Chinese. / Precis --- p.vi / 摘要 --- p.viii / Captions for Tables --- p.x / Caption for Figure --- p.xii / Abbreviations --- p.xiii / Chapter Part 1 --- Literature Review --- p.0 / Chapter Chapter 1 --- Aims and Hypothesis --- p.1 / Chapter 1.1 --- Aims --- p.3 / Chapter 1.2 --- Hypothesis --- p.4 / Chapter Chapter 2 --- Epidemiology of HBV Infection --- p.5 / Chapter 2.1 --- Global and Local Epidemiology --- p.6 / Chapter 2.2 --- Modes of Transmission --- p.8 / Chapter 2.2.1 --- Perinatal Tansmission --- p.8 / Chapter 2.2.2 --- Percutaneous Transmission --- p.8 / Chapter 2.2.3 --- Sexual Transmission --- p.8 / Chapter 2.2.4 --- Healthcare Setting and Transplantation --- p.8 / Chapter 2.2.5 --- Transfusion --- p.9 / Chapter 2.2.6 --- Other --- p.9 / Chapter Chapter 3 --- Popularity of TCM --- p.10 / Chapter 3.1 --- Traditional Chinese Medicine Use --- p.11 / Chapter 2.2 --- Regulation on TCM Practice --- p.12 / Chapter Chapter 4 --- Philosophy of TCM on HBV Infection --- p.13 / Chapter 4.1 --- Basic Principles --- p.14 / Chapter 4.1.1 --- Yin-Yang Theory --- p.14 / Chapter 4.1.2 --- Five Elements Theory --- p.14 / Chapter 4.1.3 --- Zang Fu Theory --- p.14 / Chapter 4.2 --- Pathogenesis --- p.16 / Chapter 4.3 --- Diagnosis --- p.17 / Chapter 4.4 --- Treatment --- p.20 / Chapter Chapter 5 --- Western Medicine --- p.23 / Chapter 5.1 --- Natural History of HBV Infection --- p.24 / Chapter 5.1.1 --- Replicative Phase: Immune Tolerance --- p.24 / Chapter 5.1.2 --- Replicative Phase: Immune Clearance --- p.24 / Chapter 5.1.3 --- Noreplicating (Low-Replication) Phase --- p.25 / Chapter 5.2 --- Diagnostic Tests for HBV Infection --- p.26 / Chapter 5.2.1 --- Serologic Assays --- p.26 / Chapter 5.2.2 --- Serum Enzymes --- p.26 / Chapter 5.2.3 --- HBV DNA Assays --- p.27 / Chapter Chapter 6 --- Health-related Quality of Life --- p.29 / Chapter 6.1 --- Principle and Definition --- p.30 / Chapter 6.2 --- Assessment --- p.31 / Chapter 6.2.1 --- Generic Instrument --- p.31 / Chapter 6.2.2 --- Disease-Specific Instrument --- p.32 / Chapter Part 2 --- Studies & Results --- p.33 / Chapter Chapter 7 --- Research Methodology --- p.34 / Chapter 7.1 --- Study 1: Hospital-Based Surveys on Chronic Hepatitis B Patients: TCM Use --- p.35 / Chapter 7.1.1 --- Patients --- p.35 / Chapter 7.1.2 --- Survey Instrument & Logistic --- p.35 / Chapter 7.1.4 --- Statistical Analysis --- p.36 / Chapter 7.1.4 --- Sample Size Justification --- p.36 / Chapter 7.2 --- Study 2: Hospital-Based Survey on Chronic Hepatitis B Patients: HRQoL & Psychiatric Involvement --- p.38 / Chapter 7.2.1 --- Patients --- p.38 / Chapter 7.2.2 --- Survey Instrument and Logistic --- p.38 / Chapter 7.2.3 --- Statistical Analysis --- p.39 / Chapter 7.3 --- Study 3: Population-Based Survey on Chinese Medicine Practitioners (CMPs): Practice Behavior & Knowledge Assessment --- p.41 / Chapter 7.3.1 --- Study Population --- p.41 / Chapter 7.3.2 --- Survey Instrument --- p.41 / Chapter 7.3.3 --- Statistical Analysis & Knowledge Assessment --- p.42 / Chapter 7.4 --- Study 4: TCM Consultation Agreement --- p.44 / Chapter 7.4.1 --- Patients --- p.44 / Chapter 7.4.2 --- Chinese Medicine Practitioners --- p.44 / Chapter 7.4.3 --- Questionnaire --- p.44 / Chapter 7.4.4 --- Study Design --- p.45 / Chapter 7.4.5 --- Sample Size Estimation --- p.45 / Chapter 7.4.6 --- Data Analysis --- p.45 / Chapter 7.5 --- "Study 5: TCM Interpretation of Laboratory, Imaging & HRQoL Assessment" --- p.47 / Chapter 7.5.1 --- Patients --- p.47 / Chapter 7.5.2 --- HRQoL Assessment --- p.47 / Chapter 7.5.3 --- Statistical Analysis --- p.47 / Chapter Chapter 8 --- TCM Use on Chronic Hepatitis B Patients --- p.48 / Chapter 8.1 --- Patient Characteristics --- p.49 / Chapter 8.2 --- Health-Seeking Behavior of TCM Users --- p.51 / Chapter 8.3 --- Determinants of TCM Use --- p.53 / Chapter 8.4 --- Common Herbal Ingredients Used --- p.56 / Chapter Chapter 9 --- Impacts of HBV Infection on Patients --- p.58 / Chapter 9.1 --- Patient Socio-Demographic and Clinical Characteristics --- p.59 / Chapter 9.2 --- Patient Symptoms and Anxiety /Depression --- p.61 / Chapter 9.3 --- HRQoL & its Determinants --- p.63 / Chapter 9.3.1 --- Physical Aspect of HRQoL --- p.63 / Chapter 9.3.2 --- Mental Aspect of HRQoL --- p.67 / Chapter Chapter 10 --- Chinese Medicine Practitioners' (CMP) Practice --- p.71 / Chapter 10.1 --- CMPs Demographics and Training --- p.72 / Chapter 10.2 --- Practice Behavior --- p.75 / Chapter 10.3 --- Diagnostic and Therapeutic Approach --- p.76 / Chapter 10.4 --- Professional Knowledge Assessment --- p.79 / Chapter 10.5 --- Determinants of Diagnostic Approach --- p.82 / Chapter Chapter 11 --- Agreement of TCM Diagnosis among Different CMPs --- p.85 / Chapter 11.1 --- Patients Characteristics & Disease Severity --- p.86 / Chapter 11.2 --- Agreement of TCM Diagnosis & Treatment --- p.88 / Chapter Chapter 12 --- Interpretation of TCM diagnosis --- p.93 / Chapter 12.1 --- Patients --- p.94 / Chapter 12.2 --- Clinical Characteristics --- p.96 / Chapter 12.3 --- HRQoL Assessment --- p.98 / Chapter Part 3 --- Discussion & Conclusions --- p.100 / Chapter Chapter 13 --- Discussion --- p.101 / Chapter 13.1 --- TCM Popularity and its Practice --- p.102 / Chapter 13.2 --- Impact of TCM Symptomatology & Anxiety /Depression on HRQoL --- p.107 / Chapter 13.3 --- TCM Diagnosis Consistency --- p.111 / Chapter 13.4 --- Association of TCM Diagnosis with Western Medicine --- p.114 / Chapter 13.5 --- Limitations of the Study --- p.117 / Chapter Chapter 14 --- Conclusions --- p.120 / Reference --- p.122 / List of Publications of My Work Used in This Thesis --- p.133 / Acknowledgement --- p.136 / Appendix --- p.138

Deng Xue-Long. / "January 2003." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2003. / Includes bibliographical references (p. 196-230). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Kam, Kin Ting. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2008. / Includes bibliographical references (leaves 169-192). / Abstracts in English and Chinese. / Chapter 1. --- Abstract --- p.ii / English --- p.ii / Chinese --- p.v / Chapter 2. --- Acknowledgments --- p.vii / Chapter 3. --- Abbreviations and N-glycan representation --- p.viii / Chapter 4. --- Introduction --- p.1 / Chapter 5. --- Review of Literatures --- p.2 / Chapter 5.1. --- Introduction to Liver Fibrosis --- p.2 / Chapter 5.1.1. --- Pathogenesis of Liver Fibrosis --- p.2 / Chapter 5.1.2. --- Changes of liver architecture - basis of liver fibrosis diagnosis --- p.4 / Chapter 5.2. --- Current Diagnosis of Liver Fibrosis - from Biopsy Examination to Serum Test --- p.5 / Chapter 5.3. --- Glycomics and its Potential as Biomarkers --- p.9 / Chapter 5.3.1. --- Overview of Biochemical and Functional Characteristics of Glycan --- p.13 / Chapter 5.3.2. --- N-linked and O-linked Glycosylations - A Valuable Source of Biomarkers --- p.15 / Chapter 5.3.3. --- Glycomics 一 An Uprising Approach for Biomarker Discovery --- p.17 / Chapter 5.3.4. --- Human Proteome Organisation Human Disease Glycomics/Proteome Initiative --- p.19 / Chapter 5.3.5. --- Recent Applications of Glycomics to Biomarker Discovery --- p.20 / Chapter 5.4. --- Current Technologies for Glycomic Study --- p.22 / Chapter 5.4.1. --- MALDI-TOF MS --- p.22 / Chapter 5.4.2. --- Lectin Microarray --- p.25 / Chapter 5.4.3. --- Liquid Chromatography --- p.27 / Chapter 5.4.4. --- Capillary Electrophoresis --- p.29 / Chapter 5.4.5. --- Quantitative Profiling of Tissue Glycome --- p.31 / Chapter 6 --- Project Rationales and Objectives --- p.36 / Chapter 7 --- Section 1: Methodology Development of Quantitative N- glycomic Profiling --- p.37 / Chapter 1. --- Introduction --- p.37 / Chapter 2. --- Method and Materials --- p.39 / Chapter 3. --- Results --- p.46 / Chapter 4. --- Discussion --- p.65 / Chapter 5. --- Conclusion --- p.71 / Chapter 8. --- Section 2: Serum N-glycomic Profile as Biomarker for Liver Fibrosis 一 Pilot Study --- p.73 / Chapter 1. --- Introduction --- p.73 / Chapter 2. --- Method and Materials --- p.75 / Chapter 3. --- Results --- p.79 / Chapter 4. --- Discussion --- p.86 / Chapter 5. --- Conclusion --- p.94 / Chapter 9. --- Section 3: Serum N-glycomic Profile as Biomarker for Liver Fibrosis -Verification Study --- p.96 / Chapter 1. --- Introduction --- p.96 / Chapter 2. --- Method and Materials --- p.98 / Chapter 3. --- Results --- p.104 / Chapter 4. --- Discussion --- p.137 / Chapter 5. --- Conclusion --- p.152 / Chapter 10. --- General Discussion --- p.153 / Chapter 11. --- Conclusion --- p.167 / Chapter 12. --- Original Data --- p.168 / Chapter 13. --- References --- p.169 / Chapter 14. --- Publications --- p.196